Combination of antibody-drug conjugate and immune checkpoint inhibitor

NZ795245BActive Publication Date: 2026-09-29DAIICHI SANKYO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ795245
Authority / Receiving Office
NZ · NZ
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-09-25
Filing Date
2017-12-11
Publication Date
2026-09-29
Estimated Expiration
2037-12-11

Smart Images

  • Figure 1_ABST
    Figure 1_ABST
Patent Text Reader

Abstract

A pharmaceutical composition and a treatment method, each of which is characterized in that an antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination, wherein the antibody-drug conjugate is formed by bonding a drug linker represented by formula (1) (wherein A represents an antibody-bonding position) to an antibody through a thioether bond; and a pharmaceutical composition and a treatment method, each of which is characterized in that the antibody-drug conjugate is contained and is also characterized by being used for the treatment of a disease that can be ameliorated through an anti-tumor immunity activation effect.
Need to check novelty before this filing date? Find Prior Art